STOCK TITAN
  1. Home
  2. Sec-filings
  3. RVMD
  4. [Form 4] Revolution Medicines, Inc. Insider Trading Activity

Revolution Medicines General Counsel reports 13,388-share option exercise

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) reported an insider equity transaction by its General Counsel, who is an officer of the company. On 11/18/2025, the officer exercised a stock option for 13,388 shares of common stock at an exercise price of $42.45 per share, then sold 13,388 shares of common stock on the same date at a weighted average price of $70.138 per share. After these transactions, the officer beneficially owned 50,425 shares of common stock, which includes 43,910 restricted stock units. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025.

Positive

  • None.

Negative

  • None.
Insider Cislini Jeff
Role General Counsel
Sold 13,388 shs ($939K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 13,388 $0.00 --
Exercise Common Stock 13,388 $42.45 $568K
Sale Common Stock 13,388 $70.138 $939K
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 63,813 shares (Direct)
Footnotes (1)
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. Includes 43,910 restricted stock units. This transaction was executed in multiple trades in prices ranging from $70.00 to $70.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cislini Jeff
(Last) (First) (Middle)
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
(Street)
REDWOOD CITY CA 94063
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/18/2025 M(1) 13,388 A $42.45 63,813(2) D
Common Stock 11/18/2025 S(1) 13,388 D $70.138(3) 50,425(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $42.45 11/18/2025 M(1) 13,388 03/04/2025 03/03/2031 Common Stock 13,388 $0 0 D
Explanation of Responses:
1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.
2. Includes 43,910 restricted stock units.
3. This transaction was executed in multiple trades in prices ranging from $70.00 to $70.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini 11/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did RVMD disclose in this Form 4?

Revolution Medicines, Inc. disclosed that its General Counsel exercised a stock option for 13,388 shares of common stock at $42.45 per share and sold 13,388 shares of common stock at a weighted average price of $70.138 per share on 11/18/2025.

How many RVMD shares does the reporting person own after the transaction?

Following the reported transactions, the officer beneficially owned 50,425 shares of Revolution Medicines common stock, which includes 43,910 restricted stock units.

What type of derivative security did the RVMD officer exercise?

The officer exercised a stock option (right to buy) covering 13,388 shares of Revolution Medicines common stock at an exercise price of $42.45 per share.

Were the RVMD insider transactions done under a Rule 10b5-1 plan?

Yes. The filing states that the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.

What does the weighted average sale price mean in this RVMD Form 4?

The reported sale price of $70.138 per share is a weighted average of multiple trades executed in a price range from $70.00 to $70.38 per share, inclusive.

What is the reporting person’s role at Revolution Medicines (RVMD)?

The reporting person is an officer of Revolution Medicines, Inc., serving as General Counsel.